Curis Announces Changes to its Board of Directors
Tuesday November 4, 9:39 am ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 4, 2003--Curis, Inc. (NASDAQ:CRIS - News) today announced the appointment of Kenneth I. Kaitin, Ph.D., to its Board of Directors. Dr. Kaitin is the Director of the Tufts Center for the Study of Drug Development, an academic drug policy research group providing strategic information to help drug developers, regulators, and policy makers improve the quality and efficiency of the drug development process. He also holds a faculty appointment as Associate Professor of Medicine at Tufts University School of Medicine.
"I am excited to join Curis' Board of Directors", said Dr. Kaitin. "Curis is an innovative company that has developed a promising portfolio of drug candidates and has an equally promising business model. I look forward to interacting with the Company as it continues to make progress as a drug development organization."
Dr. Kaitin replaces Ruth B. Kunath who is stepping down from the Board of Directors after having served for three years with Curis and two years with Ontogeny, Inc., one of Curis' predecessor companies. Ms. Kunath is the biotechnology portfolio manager for Vulcan Inc., the Seattle-based investment and project-management company founded by Paul G. Allen.
"It has been a real pleasure working with Dan Passeri and his management team during the development of Curis as a product-focused company," said Ms. Kunath. "In the past year, Curis has established several impressive corporate collaborations in multiple therapeutic product fields, and the addition of Dr. Kaitin to the board will continue to enhance the company's strategic focus and vision."
Daniel R. Passeri, Curis' President and Chief Executive Officer, commented, "We are very grateful to Ruth for her advice and support during the transitional years at Curis. We are also very pleased with the addition of Dr. Kaitin, who will bring new expertise and perspective to the Board as Curis continues to evolve its product development capabilities."
Aecules to modulate these pathways. Curis has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of kidney disease, neurological disorders, cancer, and alopecia (hair loss). For more information, please visit the Curis web site at www.curis.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning Curis' or management's intentions, plans, expectations or predictions of future events are forward-looking statements. Such statements may contain the words "believes", "expects", "anticipates", "plans", "estimates" or similar expressions. Forward looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from those indicated by such forward-looking statements. Actual results can be affected by, among other things, uncertainties relating to product development, clinical trials, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, changes in or an inability to execute Curis' realigned business strategy and other risk factors identified in Curis' most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release.
Contact:
For Curis, Inc.
Christopher U. Missling, Ph.D.
617-503-6587
Marc F. Charette, Ph.D.
617-503-6629
Source: Curis, Inc. |
